SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Emile Griffith

PatientEmile Griffith
Date of birth1959-02-03
IdentifiersMRN HR-BX005-SYN; SSN (made up) 000-05-6418
Document date2026-05-19
AuthorCeleste Fairbanks-Ochieng, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Two-week review of memory loss and PTSD, seen the same day by cognitive neurology. [S]

History of Present Illness

Emile Griffith returns two weeks after intake with his care partner and is seen the same day by Dr. Haddad-Lindgren at the memory clinic. He had a brain MRI this morning. His intake blood count, metabolic panel, B12 and TSH were normal. He started sertraline 25 mg each morning after intake; he had mild nausea for three days, which has gone, and no dizziness or bleeding. The nightmares about the title fight still come most nights. His first session of cognitive processing therapy is booked for next week. He missed the physical therapy evaluation booked last week: the card was mislaid and nobody called to remind him. He has had no falls and has not travelled alone since intake. He has had no thoughts of suicide. [S]

ElementDetail
MRIMild frontal-predominant atrophy; old right frontal injury; seven microbleeds; cavum septi pellucidi; hippocampi normal for age
CDRGlobal 0.5, sum of boxes 2.0
Sodium138 mmol/L two weeks into sertraline
Sertraline25 mg; nausea for three days, now gone
SafetyNo thoughts of suicide; safety plan on the refrigerator

Review of Systems

SystemResultFinding
NeurologicalPositiveForgetfulness and slowness in finding words for names; no headaches, weakness, tremor or change in walking
PsychiatricPositiveNightmares most nights, guilt about the fight, mood low some days; no hallucinations, suspiciousness or thoughts of suicide
GastrointestinalNegativeNausea in the first three days of sertraline, now gone; no diarrhea
MusculoskeletalNegativeNo falls

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Sertraline 25 mg oral tablet, one tablet each morningOne tablet each morningOral route2026-05-05 to 2026-06-16completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-05-19Body height170cmS
2026-05-19Body weight73.8kgS
2026-05-19Body mass index (BMI) [Ratio]25.5kg/m2S
2026-05-19Systolic blood pressure130mm[Hg]S
2026-05-19Diastolic blood pressure78mm[Hg]S
2026-05-19Heart rate68/minS
2026-05-19Respiratory rate14/minS
2026-05-19Body temperature36.6CelS
2026-05-19Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-05-19Sodium [Moles/volume] in Serum or Plasma138mmol/L135-145 mmol/LNormalS
2026-05-19Clinical Dementia Rating scale [CDR]0.5{score}S

Physical Exam

Vital signs recorded on 2026-05-19; see the Vital Signs section. [S]

SystemFinding
GeneralWell and warm; blood pressure 130/78 mmHg; pulse 68; weight 73.8 kg
NeurologicalCranial nerves normal; no rigidity, tremor or slowness; normal strength and reflexes; slightly wide-based gait with one side-step on tandem walking; no dysarthria
Mental statusAlert and courteous; needs cues to recall the plan from intake; tearful briefly when the fight is discussed; no psychotic symptoms; denies thoughts of suicide

Problems

ProblemClinical statusVerificationCodeProvenance
Memory loss and confusion over about a year, worse in recent months, reported by him and his care partner: repeating stories and questions, losing the thread of conversations, mixing up days, two missed appointments, and once getting lost changing trains on a familiar route; cause to be foundactiveconfirmed R41.3S — Synthetic presenting problem anchored to the documented short-term memory problems; resolved into the diagnosis at the third visit. Not a claim about his real symptoms at that age.
Post-traumatic stress disorder, chronic, after two index events (a title fight decades ago after which his opponent died, and a severe assault thirteen years ago): nightmares, unwanted images, avoidance of fight footage, guilt and self-blame, being on guard in crowds, poor sleep; PCL-5 41activeconfirmed F43.12S — Synthetic modern diagnosis at intake by clinical interview against DSM-5-TR criteria, anchored to his public words about lifelong nightmares; not a historical diagnosis.
Personal history of traumatic brain injury: repetitive head impacts over 112 professional bouts, and a severe head injury in an assault thirteen years ago with months in hospitalactiveconfirmed Z87.820S — Synthetic coding of the documented career and assault.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyCognitive testing (MoCA)At diagnosis, then yearly, or sooner with changeUp to dateMoCA 22 at intake, with delayed recall helped by cues
SurveyStaging (CDR) and function (ADL and IADL)At diagnosis, then yearlyCompleted todayGlobal CDR 0.5 (sum of boxes 2.0); independent in personal care; reminders for appointments and help with bills (Functional Activities Questionnaire 6)
LaboratoryReversible causes: blood count, metabolic panel, B12, TSH, depression, sleep apnea, hearing and visionOnce at diagnosisUp to dateCompleted at intake: blood count, metabolic panel, B12 418 pg/mL and TSH 2.1, normal; PHQ-9 9; STOP-Bang 2 (low risk); whispered-voice test and near vision normal; no anticholinergic or sedating medicines
ImagingStructural brain MRIOnce at diagnosis; repeat only with an atypical course or focal changeCompleted todayMild frontal-predominant atrophy; old right frontal encephalomalacia; seven microbleeds; cavum septi pellucidi; hippocampi normal for age; no infarct, mass or subdural collection
SurveyNeuropsychological testingAt diagnosis when the cause or stage is unclear; repeat in 12 to 18 months or with changeOrderedBooked in three weeks
LaboratoryAlzheimer's disease biomarkers (blood, CSF or amyloid PET)When the result would change diagnosis or managementDueTo be discussed with the testing results
ExaminationMedicine review for anticholinergic, sedating and fall-risk drugs (Beers)Every visitCompleted todaySertraline 25 mg only; no anticholinergic, sedating or over-the-counter sleep medicines
SurveyNeuropsychiatric symptom screen (apathy, irritability, paranoia, impulsivity)Every visitCompleted todayNo apathy, irritability, paranoia or impulsive behavior
SurveyPHQ-9 with suicide-risk review (item 9 and structured questions)Monthly during acute treatment; every visit during active treatmentUp to datePHQ-9 9 at intake, item 9 scored 0; no thoughts of suicide today; next PHQ-9 at six weeks
SurveyPCL-5Baseline, then at each chronic-care visit during treatment; response judged after 8 to 12 weeksUp to datePCL-5 41 at intake; next at six weeks
Medication safetySertraline: nausea, sleep, falls, bleeding, and sodium (SSRIs can lower sodium in older adults)Two weeks after starting and after each dose change; sodium at those pointsCompleted todayTwo weeks on 25 mg: nausea resolved; no dizziness, falls or bleeding; sodium 138 mmol/L
ReferralTrauma-focused psychotherapy (cognitive processing therapy)Weekly, about twelve sessionsReferredWith the clinic psychologist; first session next week
ExaminationFall risk (Timed Up and Go, gait and balance), STEADIAt diagnosis, yearly, and after any fallUp to dateTimed Up and Go 13 seconds at intake; one fall on ice last winter; no fall since
ReferralPhysical therapy for balance and strengthOnce, after a Timed Up and Go above 12 secondsDeferredDeviation: the evaluation booked for last week was missed because the appointment card was mislaid and no reminder call was made. No fall has occurred, so no harm is known. Corrective action: rebooked at the first opening, in about five weeks, with a reminder call to him and his care partner and the date on the wall calendar
ExaminationDriving safetyAt diagnosis and each follow-upNot indicatedHe does not drive
Self-managementTravel, money and home safetyAt diagnosis and each follow-upCompleted todayTravels with his care partner; no firearms; medicines kept by his care partner
ExaminationVascular risk factors (blood pressure, weight)Every visitCompleted todayBlood pressure 130/78 mmHg; weight 73.8 kg

Goal progress:

Guideline basis: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024); National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome (2021); VA/DoD Clinical Practice Guideline for Management of Posttraumatic Stress Disorder and Acute Stress Disorder (2023); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, Non-Alzheimer's dementia and Depression/Bipolar/Mood Disorders monographs (2026); American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023); STEADI (Stopping Elderly Accidents, Deaths and Injuries): Clinical Resources (2024)

Follow-up: Neuropsychological testing in three weeks. Six-week review with the results, PHQ-9 and PCL-5. Call the clinic or 988 at any time if thoughts of suicide arise. Next scheduled visit 2026-06-16: six-week review: neuropsychological testing, the diagnosis and the plan, PTSD treatment, safety and caregiver support. [S]